Results 261 to 270 of about 47,434 (363)

Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma [PDF]

, 2020
Suman Verma, Mathew W. Moore, Rebecca Ringler, Abhisek Ghosal, Kyle Horvath, Theodore Naef, Sheri Anvari, Philip D. Cotter, Shelly Gunn   +8 more
openalex   +1 more source

The microbiome in cancer

iMeta, Volume 4, Issue 5, October 2025.
This comprehensive review elucidates the transformative role of the human microbiome in cancer biology, revealing innovative mechanistic insights into the intricate tumor–microbe interactions across diverse organ systems. This work highlights the clinical and translational value of novel microbiome‐based biomarkers for early detection, prognosis, and ...
Anqi Lin, Minying Xiong, Aimin Jiang, Lihaoyun Huang, Hank Z. H. Wong, Suyin Feng, Chunyan Zhang, Yu Li, Li Chen, Hao Chi, Pengpeng Zhang, Bicheng Ye, Hengguo Zhang, Nan Zhang, Lingxuan Zhu, Weiming Mou, Junyi Shen, Kailai Li, Wentao Xu, Haoxuan Ying, Cangang Zhang, Dongqiang Zeng, Jindong Xie, Xinpei Deng, Qi Wang, Jianying Xu, Wenjie Shi, Chang Qi, Chunrun Qu, Xufeng Huang, András Hajdu, Chaoqun Li, Changmin Peng, Xuanye Cao, Guangsheng Pei, Lin Zhang, Yujia Huo, Jiabao Xu, Antonino Glaviano, Attila Gábor Szöllősi, Sicheng Bian, Zhengrui Li, Hailin Tang, Bufu Tang, Zaoqu Liu, Jian Zhang, Kai Miao, Quan Cheng, Ting Wei, Shuofeng Yuan, Peng Luo   +50 more
wiley   +1 more source

Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma

British Journal of Cancer, 2022
K. Shohdy, D. Villamar, Yen Cao, J. Trieu, K. Price, R. Nagy, S. Tagawa, A. Molina, C. Sternberg, D. Nanus, J. Mosquera, O. Elemento, G. Sonpavde, P. Grivas, N. Vogelzang, B. Faltas   +15 more
semanticscholar   +1 more source

Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma [PDF]

, 2020
al., et, Bartlett, Nancy L., Cashen, Amanda, Edwin, Natasha, Ghobadi, Armin, Kahl, Brad, Mehta-Shah, Neha, Merryman, Reid W.   +7 more
core   +1 more source

ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib [PDF]

, 2020
Atocha Romero, Roberto Serna‐Blasco, Cristina Alfaro, Estela Sánchez‐Herrero, Miguel Barquín, María C. Turpín, Sofía Chico, Sandra Sanz‐Moreno, Alejandro Rodríguez-Festa, Raquel Laza‐Briviesca, Alberto Cruz‐Bermúdez, Virginia Calvo, Ana Royuela, Mariano Provencio   +13 more
openalex   +1 more source

Comprehensive Genetic Analysis of NF2 in Sporadic Vestibular Schwannoma

Laryngoscope Investigative Otolaryngology, Volume 10, Issue 5, October 2025.
Comprehensive genetic analyses, including whole‐exome sequencing, methylation analysis, and MLPA, are essential for accurately identifying NF2 inactivation mechanisms in sporadic vestibular schwannomas. The findings suggest that NF2 methylation may contribute to variations in clinical presentation.
Takeshi Wakabayashi, Koichiro Wasano, Kohei Nakamura, Makoto Hosoya, Ryutaro Kawano, Reika Takamatsu, Masafumi Ueno, Marie N. Shimanuki, Nobuyoshi Tsuzuki, Takanori Nishiyama, Takenori Akiyama, Masahiro Toda, Hiroshi Nishihara, Hiroyuki Ozawa, Naoki Oishi   +14 more
wiley   +1 more source

Circulating tumour DNA assays in focus: highlights from ASCO 2025 for clinicians. [PDF]

BJC Rep
Coakley MF, Pascual J, O'Reilly S.
europepmc   +1 more source

Individualized ctDNA Fingerprints to Monitor Treatment Response and Recurrence in Multiple Cancer Types [PDF]

, 2019
Jiaping Li, Wei Jiang, Jinwang Wei, Jianwei Zhang, Linbo Cai, Minjie Luo, Zhan Wang, Wending Sun, Chen Wang, Chun Dai, Guan Wang, Qiang Xu, Yanhong Deng   +12 more
openalex   +1 more source

Targeted Therapies in the Most Common Advanced Solid Tumors, Drug Resistance, and Counteracting Progressive Micrometastatic Disease: The Next Frontier of Research

MedComm, Volume 6, Issue 10, October 2025.
In TME, undetectable DCCs (panel A) join with a low tumor burden along with low immune suppression, that favor successful immune manipulation through immune suppression inhibiting immune‐therapy. This moves the immune balance toward the immune response and likely makes more stable the dormant state of DCCs in the unstable metastatic niche and/or allows
Andrea Nicolini, Paola Ferrari, Roberto Silvestri, Dario A. Bini   +3 more
wiley   +1 more source

Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and/or chemotherapy. [PDF]

J Immunother Cancer
Andrews HS, Zariffa N, Nishimura KK, Deng Y, Eisele M, Ensor J, Espenschied C, Fabrizio D, Goren EM, Haddad V, Liu MC, Modi D, Moesta AK, Quinn KJ, Rosenthal A, Vega DM, Zou W, Hoering A, Stewart M, Allen J.   +19 more
europepmc   +1 more source